More Stories

Informist, Friday, Sept. 26, 2025

 

--Pharmexcil: India's global pharma exports growth in FY26 seen at 6-7%

--Pharmexcil: Expect India exports to US rise 10-11% on year in FY26

--Pharmexcil:  Continuously evaluating challenges in pharma exports

--Pharmexcil:  Quality, low cost is the strength of Indian generic medicines

--Pharmexcil: US enjoying cost savings on pharma generics for past 10 years

--Pharmexcil: US saving $200 bln/year in costs from Indian generics imports

--Pharmexcil: Indian generic products a cost saving opportunity to US

--Indian pharma alliance: India patented, branded pdt sales to US very small

--Indian pharma alliance: US pharma tariffs not applicable to generics

 

By Narayana Krishna

 

HYDERABAD - Pharmaceutical Exports Promotion Council of India Chairman Namit Joshi Friday said the proposed 100% tariff on pharmaceutical exports to the US would not affect Indian generic exports, as the proposed move is applicable to only branded and patented products. Pharmaceutical Exports Promotion Council of India, or Pharmexcil, works under the Ministry of Commerce and helps the industry facilitate exports opportunities and growth.

 

"We don't foresee much of an impact now because this has been levied (100% tariff) on patented and branded products and India does not export patented or branded. So, as of now, we don't foresee much of a challenge," Joshi told Informist.

 

US President Donald Trump has announced 100% tariff on branded and patented pharmaceutical imports, which will be effective Oct. 1. Trump took to social media platform Truth Social and said pharmaceutical companies that were constructing their manufacturing units in the US would be exempted from the fresh levies.

 

Indian generics is a huge cost saving option for the US, Joshi said, adding that any move on imposing tariffs on generics might increase their costs significantly.

 

"If someone has to take a call (on imposing tariff on generics too), then it has to be at the cost, it has to be at certain expense of reassuring because what we supply, at what price we supply, I think there are very few countries who can afford to serve US at the cost what we serve to them. So, approximately, every year we make them save $200 billion," he said.

 

The lower cost of generic medicines itself is a huge value saving for the US; otherwise, it would cripple the economy, he said.

 

Asked about the possibility of extending the tariffs to generics going forward, Joshi said, "It is too difficult to say right now. Because you have to evaluate all the aspects of commercials when you try to levy some tariff. Supply chain resilience would be one of the core factors which India can offer and has been offering to US continuously for so many long years." 

 

Joshi said the council is continuously evaluating any future risks and challenges for Indian exports. "Right now, we are very well-placed in terms of the affordability and quality of medicines," he said.

 

Despite challenges, Pharmexcil expects India's total pharma exports to global markets to rise 6-7% in 2025-26 (Apr-Mar), while exports to the US are expected to see 10-11% on year growth, Joshi said. For FY25, India's overall pharma exports were at $30.46 billion, while exports to the US were at $10.5 billion.

 

Expressing similar views, Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said the proposed tariff was applicable only to patented and branded products and it wouldn't affect the industry, as it doesn't export much of these categories.  End

 

US$1 = INR 88.72

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.